Journal of Molecular Neuroscience

, Volume 66, Issue 3, pp 383–389 | Cite as

OIP5 Expression Sensitize Glioblastoma Cells to Lomustine Treatment

  • Dorival Mendes Rodrigues-Junior
  • Thaís Priscila Biassi
  • Viviane Carlin
  • Marcus Vinicius Buri
  • Ana Claudia Torrecilhas
  • Karina Ramalho Bortoluci
  • André Luiz Vettore


Glioblastoma (GBM) is an incurable disease ranked among the deadliest solid cancers worldwide. A better understanding on the molecular aspects of this malignancy could contribute to the development of new treatment strategies and help to improve survival rates. Previously, our group had shown that GBM patients expressing the cancer/testis antigen Opa Interacting Protein 5 (OIP5) present a longer survival period than the OIP5-negative group. The main goal of this study was to evaluate the OIP5 contribution to GBM tumorigenesis and assess the role of OIP5 in GBM cell response to lomustine, an alkylating agent used in the treatment of this malignancy. So, the effect of OIP5 knockdown was evaluated in A172 and T98G GBM cell lines. Our results demonstrated that downregulation of the OIP5 stimulates glioma cell viability and inhibits cell death-induced necrosis prompted by lomustine. In conclusion, our data shows that OIP5 expression in GBM cells seems to be able to enhance lomustine cytotoxic effects, reinforcing that this gene is a potential therapeutic target and putative molecular biomarker for treatment response in GBM.


Glioblastoma OIP5 Lomustine Drug resistance 


Financial Support

This study was funded by São Paulo Research Foundation (FAPESP grant 2012/14837-7; 2010/20218-2). TPB and DMR-Jr received a scholarship from São Paulo Research Foundation (FAPESP, 2011/15118-1 and 2012/01597-8, respectively). ALV has a National Counsel of Technological and Scientific Development scholarship (CNPq, 300936/2015-0).

Compliance with Ethical Standards

Conflict of Interest

The authors declare that they have no conflict of interest.

Ethical Approval

This work was approved by the ethics committees of the São Paulo Federal University (CEP-UNIFESP) number 1015/11.

Supplementary material

12031_2018_1184_MOESM1_ESM.doc (31 kb)
ESM 1 (DOC 31 kb)


  1. Adamson C, Kanu OO, Mehta AI, di C, Lin N, Mattox AK, Bigner DD (2009) Glioblastoma multiforme: a review of where we have been and where we are going. Expert Opin Investig Drugs 18(8):1061–1083CrossRefGoogle Scholar
  2. Batchelor TT, Mulholland P, Neyns B, Nabors LB, Campone M, Wick A, Mason W, Mikkelsen T, Phuphanich S, Ashby LS, DeGroot J, Gattamaneni R, Cher L, Rosenthal M, Payer F, Jürgensmeier JM, Jain RK, Sorensen AG, Xu J, Liu Q, van den Bent M (2013) Phase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma. J Clin Oncol 31(26):3212–3218CrossRefGoogle Scholar
  3. Berte N, Piée-Staffa A, Piecha N et al (2016) Targeting homologous recombination by pharmacological inhibitors enhances the killing response of glioblastoma cells treated with alkylating drugs. Mol Cancer Ther 15(11):2665–2678CrossRefGoogle Scholar
  4. Chun HK, Chung KS, Kim HC, Kang JE, Kang MA, Kim JT, Choi EH, Jung KE, Kim MH, Song EY, Kim SY, Won MS, Lee HG (2010) OIP5 is a highly expressed potential therapeutic target for colorectal and gastric cancers. BMB Rep 43(5):349–354CrossRefGoogle Scholar
  5. Freitas M, Malheiros S, Stávale JN, Biassi TP, Zamunér FT, de Souza Begnami M, Soares FA, Vettore AL (2013) Expression of cancer/testis antigens is correlated with improved survival in glioblastoma. Oncotarget 4(4):636–646CrossRefGoogle Scholar
  6. Gilbert MR, Wang M, Aldape KD et al (2013) Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial. J Clin Oncol 10(32):4085–4091CrossRefGoogle Scholar
  7. Gong M, Xu Y, Dong W, Guo G, Ni W, Wang Y, Wang Y, An R (2013) Expression of Opa interacting protein 5 (OIP5) is associated with tumor stage and prognosis of clear cell renal cell carcinoma. Acta Histochem 115(8):810–815CrossRefGoogle Scholar
  8. Harvey KA, Xu Z, Saaddatzadeh MR, Wang H, Pollok K, Cohen-Gadol AA, Siddiqui RA (2015) Enhanced anticancer properties of lomustine in conjunction with docosahexaenoic acid in glioblastoma cell lines. J Neurosurg 122(3):547–556CrossRefGoogle Scholar
  9. Koinuma J, Akiyama H, Fujita M et al (2012) Characterization of an Opa interacting protein 5 involved in lung and esophageal carcinogenesis. Cancer Sci 103(3):577–586CrossRefGoogle Scholar
  10. Lee SM, Thatcher N, Crowther D, Margison GP et al (1994) Inactivation of O6-alkylguanine-DNA alkyltransferase in human peripheral blood mononuclear cells by temozolomide. Br J Cancer 69(3):452–456CrossRefGoogle Scholar
  11. Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25(4):402–408CrossRefGoogle Scholar
  12. Mobasheri MB, Shirkoohi R, Modarressi MH (2015) Cancer/testis OIP5 and TAF7L genes are up-regulated in breast cancer. Asian Pac J Cancer Prev 16(11):4623–4628CrossRefGoogle Scholar
  13. Nakamura Y, Tanaka F, Nagahara H, Ieta K, Haraguchi N, Mimori K, Sasaki A, Inoue H, Yanaga K, Mori M (2007) Opa interacting protein 5 (OIP5) is a novel cancer-testis specific gene in gastric cancer. Ann Surg Oncol 14(2):885–892CrossRefGoogle Scholar
  14. Pegg AE, Dolan ME, Moschel RC (1995) Structure, function, and inhibition of O6-alkylguanine-DNA alkyltransferase. Prog Nucleic Acid Res Mol Biol 51:167–223CrossRefGoogle Scholar
  15. Staberg M, Michaelsen SR, Rasmussen RD, Villingshøj M, Poulsen HS, Hamerlik P (2017) Inhibition of histone deacetylases sensitizes glioblastoma cells to lomustine. Cell Oncol (Dordr) 40(1):21–32CrossRefGoogle Scholar
  16. Stupp R, Mason WP, van den Bent MJ et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 10(10):987–996CrossRefGoogle Scholar
  17. Stupp R, Hegi ME, Mason WP, van den Bent M, Taphoorn MJ, Janzer RC, Ludwin SK, Allgeier A, Fisher B, Belanger K, Hau P, Brandes AA, Gijtenbeek J, Marosi C, Vecht CJ, Mokhtari K, Wesseling P, Villa S, Eisenhauer E, Gorlia T, Weller M, Lacombe D, Cairncross JG, Mirimanoff RO, European Organisation for Research and Treatment of Cancer Brain Tumour and Radiation Oncology Groups, National Cancer Institute of Canada Clinical Trials Group (2009) Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 10:459–466CrossRefGoogle Scholar
  18. Taal W, Oosterkamp HM, Walenkamp AM et al (2014) Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial. Lancet Oncol 15(14):943–953CrossRefGoogle Scholar
  19. Weller M, van den Bent M, Hopkins K, Tonn JC, Stupp R, Falini A, Cohen-Jonathan-Moyal E, Frappaz D, Henriksson R, Balana C, Chinot O, Ram Z, Reifenberger G, Soffietti R, Wick W, European Association for Neuro-Oncology (EANO) Task Force on Malignant Glioma (2014) EANO guideline for the diagnosis and treatment of anaplastic gliomas and glioblastoma. Lancet Oncol 15(9):e395–e403CrossRefGoogle Scholar
  20. Wick W, Puduvalli VK, Chamberlain MC, van den Bent MJ, Carpentier AF, Cher LM, Mason W, Weller M, Hong S, Musib L, Liepa AM, Thornton DE, Fine HA (2010) Phase III study of enzastaurin compared with lomustine in the treatment of recurrent intracranial glioblastoma. J Clin Oncol 28(7):1168–1174CrossRefGoogle Scholar
  21. Williams JM, Chen GC, Zhu L, Rest RF (1998) Using the yeast two-hybrid system to identify human epithelial cell proteins that bind gonococcal Opa proteins: intracellular gonococci bind pyruvate kinase via their Opa proteins and require host pyruvate for growth. Mol Microbiol 27(1):171–186CrossRefGoogle Scholar
  22. Yang Q, Liu HY, Zhang YW, Wu WJ, Tang WX (2010) Anandamide induces cell death through lipid rafts in hepatic stellate cells. Gastroenterol Hepatol 25(5):991–1001CrossRefGoogle Scholar
  23. Yazarloo F, Shirkoohi R, Mobasheri MB, Emami A, Modarressi MH (2013) Expression analysis of four testis-specific genes AURKC, OIP5, PIWIL2 and TAF7L in acute myeloid leukemia: a gender-dependent expression pattern. Med Oncol 30(1):368CrossRefGoogle Scholar
  24. Zimmermann M, Meyer N (2011) Annexin V/7-AAD staining in keratinocytes. Methods Mol Biol 740:57–63CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  • Dorival Mendes Rodrigues-Junior
    • 1
  • Thaís Priscila Biassi
    • 1
  • Viviane Carlin
    • 1
  • Marcus Vinicius Buri
    • 2
  • Ana Claudia Torrecilhas
    • 3
  • Karina Ramalho Bortoluci
    • 1
  • André Luiz Vettore
    • 1
    • 4
  1. 1.Department of Biological ScienceUniversidade Federal de São PauloDiademaBrazil
  2. 2.Department of BiochemistryUniversidade Federal de São PauloSão PauloBrazil
  3. 3.Department of Pharmaceutical ScienceUniversidade Federal de São PauloDiademaBrazil
  4. 4.Laboratório de Biologia Molecular do CâncerUNIFESPSão PauloBrazil

Personalised recommendations